Cancer incidence and spectrum among Uygurs in Hotan District in China |
| |
| Affiliation: | 1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China;2. Hotan District People’s Hospital, Hotan, Xinjiang 848000, China;1. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA;2. Biomedical Statistics Research Core, University of Vermont, Burlington, VT, USA;3. Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA;1. Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain;2. Tobacco Control Unit, Cancer Prevention and Control Program, Institut Català d′Oncologia, L′Hospitalet de Llobregat, Barcelona, Spain;3. Tobacco Control Research Group, Epidemiology, public health, cancer prevention and palliative care program, Institut d′Investigació Biomèdica de Bellvitge - IDIBELL, L′Hospitalet de Llobregat, Spain;4. School of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;5. Center for Biomedical Research in Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain;6. Group of Integrative Pharmacology and Systems Neuroscience, Neurosciences Programme, IMIM (Hospital del Mar Medical Research Institute), Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;7. Addictions Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain;8. Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;1. Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran;2. Department of Statistics and Information Technology, Golestan University of Medical Sciences, Gorgan, Iran;3. Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;4. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran;5. Office of the Director, International Agency for Research on Cancer (IARC), Lyon, France;6. Omid Cancer Research Center, Omid Preventive Medicine and Heath Promotion Center, Golestan University of Medical Sciences, Gorgan, Iran;1. U1086 "ANTICIPE" INSERM-University of Caen Normandy, Centre François Baclesse, 3, Avenue du Général Harris, 14000 Caen, France;2. Department of Hepato-Gastroenterology and Digestive Oncology, Rouen University Hospital, 1 rue de Germont, 76000 Rouen, France;3. Digestive Tumour Registry of Calvados, Centre François Baclesse, 3, Avenue du Général Harris, 14000 Caen, France;4. Cancer Screening Center of Normandy, 28 rue Bailey, 14000, Caen, France;5. Public Health Department, Caen University Hospital, Avenue de la Côte de Nacre, 14000, Caen, France;1. Department of Ultrasonography, Xin Hua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Chongming Branch, No. 25 Nanmen Road, Chongming, Shanghai 202150, China;2. The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China;3. Community Health Service Center, No. 59 Fengnan Road, Changxing town, Chongming district, Shanghai 201913, China;4. Department of Cancer prevention, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China;5. Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Er Road, Shanghai 200025, China;1. Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia;2. Douglass Hanly Moir Pathology, Macquarie Park and Department of Clinical Medicine, Faculty of Medicine, Health and Human Science, Macquarie University, Sydney, Australia;3. Cancer Epidemiology Division, Cancer Council Victoria, and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia;4. Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia;5. Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia;6. St. Vincent''s Hospital, Sydney and University of New South Wales, Sydney, New South Wales, Australia;7. Department of Haematology, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia;8. Concord Repatriation General Hospital and University of Sydney, Concord, New South Wales, Australia;9. Clinical Haematology, Monash Health and Monash University, Clayton, Australia;10. New South Wales Health Pathology and University of New South Wales, Sydney, New South Wales, Australia;11. St. George Hospital, Kogarah and University of New South Wales, Sydney, New South Wales, Australia;12. Liverpool Hospital, Liverpool and Western Sydney University, New South Wales, Australia;13. Gosford Hospital and The University of Newcastle, New South Wales, Australia;14. Rural Medical School and Border Medical Oncology Research Unit, Albury, New South Wales, Australia;15. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;p. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia;q. The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia |
| |
| Abstract: | Cancer is the leading cause of death in China and a significant public health problem with increasing incidence and fatality rates. The Han nationality is the main ethnic group in China, and many reports on the epidemiology of cancers in Han nationality are published. However no studies report the cancer spectrum of Uygurs which are one of the minority nationalities in China. Hence, we present incidence and mortality numbers of different cancers for the Uygur patients for the period 2018–2020 in Hotan District where Uygur population accounts for 99 %. During the 3-year study period, 2509 new Uygur cancer cases were registered, comprising 774 men and 1735 women. Cervical cancer was the most common, followed by esophageal, breast, gastric and colorectal cancers. The most common cancers in women and men were cervical cancer and esophageal cancer, respectively. In conclusion, the cancer spectrum in Hotan is different from other regions of China and our research revealed the cancer incidence in Hotan, which could help us to take appropriate measures to reduce the incidence rate. |
| |
| Keywords: | Hotan district Uygurs Cancer incidence Cancer control |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
